PF-06755347

N/A

Report date: 2024/11/29 10:49:51

Base Information

Drug NamePF-06755347

Drug Alias NameGL-2045PF-06755347

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionImmunomodulatorsComplement C1q subcomponent stimulants

TargetsComplement C1q subcomponent

Therapy Area/IndicationsPurpura, Thrombocytopenic, Idiopathic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumUnited StatesNew Zealand +[5]

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGliknik Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsPurpura, Thrombocytopenic, Idiopathic

ATC CodeN/A